SCHEMBL6077709

SCHEMBL6077709

COC(=O)c1cccc(NS(=O)(=O)c2cc(O)c3ccc(NC(=O)Nc4ccc5c(O)cc(S(=O)(=O)Nc6cccc(C(=O)OC)c6)cc5c4)cc3c2)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TCF4 P15884 2/20 0.57
CTNNB1 P35222 2/20 0.57
PRMT1 Q99873 2/20 0.55
IDH1 O75874 1/20 0.54
NPC1 O15118 2/20 0.53
MAPT P10636 2/20 0.53
RAB9A P51151 2/20 0.53
SIRT1 Q96EB6 1/20 0.53
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 1/20 0.52
POLB P06746 1/20 0.51
PLAU P00749 2/20 0.49
PLAT P00750 1/20 0.48
PFKFB3 Q16875 1/20 0.48
PFKFB4 Q16877 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7520951 0.96 TCF4 (0.53) TCF4CTNNB1PRMT1IDH1NPC1
SCHEMBL6428056 0.90 PRMT1 (0.58) PRMT1IDH1SIRT1PLAU
SCHEMBL6078536 0.89 PRMT1 (0.60) PRMT1MAPTSIRT1MEN1KMT2A
SCHEMBL6078502 0.88 PRMT1 (0.58) PRMT1SIRT1MEN1KMT2APOLB
SCHEMBL28327806 0.87 TCF4 (0.61) TCF4CTNNB1RAB9APOLBPLAU
SCHEMBL6078100 0.85 TCF4 (0.68) TCF4CTNNB1IDH1NPC1MAPT
SCHEMBL6078550 0.85 PRMT1 (0.68) PRMT1MAPTSIRT1MEN1KMT2A
SCHEMBL6427793 0.85 PRMT1 (0.55) PRMT1MAPTSIRT1CYP2C9CYP2C19
SCHEMBL6078558 0.84 TCF4 (0.65) TCF4CTNNB1IDH1NPC1MAPT
SCHEMBL6078726 0.83 PRMT1 (0.72) PRMT1MAPTSIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071231-B2 Naphthalene ureas as glucose uptake enhancers TELIK, INC. (US) 2006-07-04 US disclosed
EP-1181271-B1 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2005-01-19 EP disclosed
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers SPEVAK WAYNE R (US) 2003-07-17 US disclosed
US-6458998-B1 NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS TELIK, INC. 2002-10-01 US disclosed
WO-2000071506-A9 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers GPR119, SLC2A8, SLC2A1 TCF4 1419/4885CTNNB1 2908/4885PRMT1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.